Patrick M Dillon MD

Oncology•Charlottesville, VA

Associate Professor of Oncology, University of Virginia School of Medicine

Join to View Full Profile

1240 Lee StCharlottesville, VA 22908
Phone+1 434-924-9333
Fax+1 434-244-7526

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Virginia Medical CenterResidency, Internal Medicine, 2004 - 2007
University of North Carolina at Chapel Hill School of MedicineClass of 2004

Certifications & Licensure

VA State Medical License 2004 - 2026
NC State Medical License 2007 - 2022
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012

Clinical Trials

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer Start of enrollment: 2012 Jul 01
Terminated
Phase 1
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer Start of enrollment: 2017 Sep 25
Terminated
Phase 1
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy Start of enrollment: 2019 Jan 29
Completed
Phase 1
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones Start of enrollment: 2020 Aug 04
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrol...
Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins
Journal for Immunotherapy of Cancer. 2025-02-27
Oesophageal adenocarcinoma presenting with synchronous brain metastases.
Derek Petrosian, Camilo E Fadul, Matthew Reilley, Patrick Dillon
BMJ Case Reports. 2025-01-31
A comprehensive review of current treatment modalities for leptomeningeal carcinomatosis in breast cancer.
Charles D Morris, Clare Humphrey, Patrick Dillon
Critical Reviews in Oncology/hematology. 2024-12-01

Press Mentions

Theraclion Announces First Patient Inclusion in Early-Stage Breast Cancer StudyMarch 9th, 2022
UVA Cancer Center to Expand Use of Theraclion’s HIFU System in Cancer Treatment ResearchJune 1st, 2021
Focused Ultrasound Symposium Showcases Latest Advances in Noninvasive Therapy for Brain Disorders, Cancer and Other Major DiseasesOctober 31st, 2018
Join now to see all